Par Pharmaceutical, Inc.

151 articles about Par Pharmaceutical, Inc.

• Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant®

  6/15/2023

  Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda's Dexilant®.

• Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

  1/4/2022

  Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Merz's CUVPOSA® 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

• Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

  1/10/2020

  Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. have executed a Settlement Agreement with the State of Oklahoma.

• Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States

  12/10/2019

  Endo International plc announced that one of its operating companies, Par Pharmaceutical, has received approval for and launched generic Afinitor® 2.5 mg, 5 mg and 7 mg tablets.

• Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product

  5/1/2019

  One vial of product was observed containing a glass fragment after reconstitution. 

• Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

  3/15/2019

  Endo International plc announced that Par Pharmaceutical, Inc., its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount.

• Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited

  2/27/2019

  Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.

• 

  A Deeper Look at Drug Shortages in the U.S.

  2/1/2019

  Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.

• Endo Begins Shipment of Authorized Generic Version of INVANZ® (ertapenem for injection) in the United States

  7/27/2018

  Endo International plc announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's INVANZ® (ertapenem for injection)

• Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States

  7/2/2018

  Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets.

• Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case

  5/14/2018

  Indivior PLC today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics Inc., entered into a settlement agreement with Par Pharmaceutical, Inc., Par Pharmaceutical Companies Inc., Endo International PLC and IntelGenx Technologies Corp., resolving patent litigation related to SUBOXONE® Sublingual Film.

• Endo Obtains Preliminary Injunction Against QuVa Pharma, Inc. Preventing Marketing and Release of Vasopressin Product

  3/1/2018

  Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict®, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration.

• Intellipharmaceutics Reports On Launch Of Additional Strengths Of Generic Focalin XR By Par Pharma

  5/25/2017

• IntelliPharmaCeutics Reports On Launch Of Additional Strengths Of Generic Focalin XR By Par Pharma

  1/6/2017

• Endo International Announces Termination Of HSR Act Waiting Period In Connection With Its Proposed Acquisition Of Par Pharma

  9/25/2015

• Par Pharma Begins Shipment Of Generic AndroGel 1%

  9/2/2015

• Par Pharma Begins Shipment Of Generic Megace ES

  7/29/2015

• Endo Pharmaceuticals Continues Expansion With $8.05 Billion Acquisition of Par Pharma

  5/18/2015

• PE Firm-Owned Par Pharma Files for $100 Million IPO

  3/16/2015

• Par Pharmaceutical, Inc. Announces Fourth-Quarter And Full-Year 2014 Conference Call

  3/6/2015